Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.66 |
| ▸ | CTSL | P07711 | 4/20 | 0.61 |
| ▸ | CTSB | P07858 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7600777 | 0.89 | CTSL (0.61) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL1264469 | 0.89 | CTSL (0.61) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL2409535 | 0.87 | CAPN1 (0.66) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL30688477 | 0.85 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL30241933 | 0.85 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL16095807 | 0.85 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL8668091 | 0.85 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL8100557 | 0.85 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL12052836 | 0.85 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL10049956 | 0.85 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157152-A | Compositions and methods for improving the efficacy of a drug | 赫利昂生物股份有限公司 | 2023-05-23 | — | — | CN | claimed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2021231872-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | HEALION BIO, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| US-8232240-B2 | Inhibitors of enveloped virus infectivity | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-07-31 | — | — | US | claimed |
| EP-1827478-A4 | METHODS OF TREATMENT FOR INJURED OR DISEASED JOINTS | MUCOSAL THERAPEUTICS LLC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20090053263-A1 | Inhibitors of Enveloped Virus Infectivity | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-02-26 | — | — | US | claimed |
| US-20080139458-A1 | Lubricating a joint in a mammal by administering lubricin and an enzyme inhibitor like Z-Leu-Leu-Leu-fluoromethyl ketone (Z-LLL-FMK) | MUCOSAL THERAPEUTICS | 2008-06-12 | — | — | US | claimed |
| EP-1827478-A2 | METHODS OF TREATMENT FOR INJURED OR DISEASED JOINTS | Mucosal Therapeutics LLC (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006091610-A2 | INHIBITORS OF ENVELOPED VIRUS INFECTIVITY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| WO-2006060473-A2 | METHODS OF TREATMENT OF INJURED OR DISEASED JOINTS WITH LUBRICIN COMPOSITIONS | MUCOSAL THERAPEUTICS LLC (US) | 2006-06-08 | — | — | WO | claimed |
| CN-115066207-B | Method and system for menstrual group analysis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-26 | — | — | CN | disclosed |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | UNIV CHICAGO (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230257698-A1 | FETAL TROPHOBLAST COMPOSITIONS AND METHODS | NEXTGEN JANE, INC. | 2023-08-17 | — | — | US | disclosed |
| CN-116367849-A | Therapeutic agent derived from nucleic acid | 芝加哥大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20080139458-A1 | Lubricating a joint in a mammal by administering lubricin and an enzyme inhibitor like Z-Leu-Leu-Leu-fluoromethyl ketone (Z-LLL-FMK) | MUCOSAL THERAPEUTICS | 2008-06-12 | — | — | US | disclosed |
| US-20070197438-A1 | Dynamin mediated diseases and associated methods and products | THE GENERAL HOSPITAL CORPORATION (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2007056435-A2 | DYNAMIN MEDIATED DISEASES AND ASSOCIATED METHODS AND PRODUCTS | THE GENERAL HOSPITAL CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006091610-A2 | INHIBITORS OF ENVELOPED VIRUS INFECTIVITY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | TACR1 3337/4885CTSL 13/4885CTSB 2/4885 |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | NSUN2, NSUN3, POLRMT | TACR1 3829/4885CTSL 370/4885CTSB 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.